摘要
目的评估重组人血管内皮抑素（恩度）联合同期放化疗不可手术切除Ⅲ期非小细胞肺癌（NSCLC）的有效性及安全性。方法2009--2011年入组的47例患者6～7周内接受三维适形放疗60—66Gv，放疗同期多西他赛65mg／m2加顺铂65mg／m2化疗两程，放疗前1周及第2、4、6周每天接受恩度静滴7．5mg／m2。完成治疗4周后按RECIST 1．1标准评价近期疗效，根据CTCAE3．0评估不良反应。结果44例患者完成治疗和不良反应评价，42例完成近期疗效评价。完全缓解5例，部分缓解29例，稳定3例，进展5例，有效率为77％。1年生存率、无进展生存率分别为81％、51％。死亡12例，2例死于不良反应，8例死于肿瘤，2例死因不明。3、4级中性粒细胞减少19例，3级急性放射性食管炎和肺炎各4例。结论恩度联合同期放化疗不可手术切除Ⅲ期NSCLC近期疗效和耐受性良好，值得进一步研究。
Objective To evaluate the efficacy and safety of recombinant endostatin （Endostar） combined with concurrent radio-chemotherapy （CRCT） in patients with unresectable stage m non-small cell lung cancer （NSCLC）. Methods From March 2009 to November 2011,47 patients received three- dimensional conformal radiotherapy of 60 - 66 Gy in 30 - 33 fractions over 6 - 7 weeks And concurrent chemotherapy of docetaxel 65 mg/m2 and cisplatin 65 mg/m2. Endostar was administered once a week before and on week 2, 4, 6 during CRCT at a dose level of 7.5 mg/m2/d. Tumor response was evaluated with thoracic CT scans performed 4 weeks after completion of treatment in accordance with RECIST 1.1 criteria. Acute toxicities were evaluated in accordance with CTCAE 3.0. Results Forty-four patients completed treatment and toxicity evaluation, 42 patients completed evaluation of efficacy. Five patients achieved complete response, 29 partial response, 3 stable disease, and 5 progressive disease, 2 were not assessed. Overall response rate was 77%. One-year overall survival rate was 81% , and one-year progression-free survival rate was 51%. Twelve patients died, 2 died of treatment related toxicities, 8 of cancer, and 2 of unknown causes. Nineteen patients developed grade 3/4 neutrocytopenia, grade 3 acute esophagitis and pneumonitis were observed in 4 and 4 patients, respectively, and 1 patient died of pneumonitis. No patient developed cardiovascular toxicities and hemorrhage. Conclusions Endostar combined with CRCT for unresectable stage m NSCLC was safe and the short term outcomes were promising. Further investigations are warranted.
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2012年第6期500-503,共4页
Chinese Journal of Radiation Oncology
基金
国家自然科学基金项目（30872974,81172116）
广东省科技计划项目（20098030801154）
关键词
癌
非小细胞肺
放化疗法
血管内皮抑素
预后
Carcinoma, non-small cell lung/radio-chemotherapy
Endostar
Prognosis
